Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

ResMed Q3 2024 Adj EPS $2.13 Beats $1.91 Estimate, Sales $1.200B Beat $1.167B Estimate

Author: Benzinga Newsdesk | April 25, 2024 04:06pm
ResMed (NYSE:RMD) reported quarterly earnings of $2.13 per share which beat the analyst consensus estimate of $1.91 by 11.52 percent. The company reported quarterly sales of $1.200 billion which beat the analyst consensus estimate of $1.167 billion by 2.82 percent. This is a 7.44 percent increase over sales of $1.117 billion the same period last year.

Posted In: RMD


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist